Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
25.04. | Antibe Therapeutics Inc (2): Antibe Therapeutics to be delisted from TSX May 24 | 3 | Stockwatch | ||
24.04. | Antibe Therapeutics Inc (2): Antibe's CCAA proceedings ended, receiver appointed | 1 | Stockwatch | ||
24.04. | Antibe Therapeutics Inc. Announces Appointment of Receiver | 57 | Business Wire | TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX: ATE) announced that the Company's request for an extension of its previously announced stay of proceedings under... ► Artikel lesen | |
19.04. | Antibe Therapeutics Inc (2): Antibe Therapeutics obtains CCAA stay extension | 1 | Stockwatch | ||
16.04. | Antibe Therapeutics Inc (2): Antibe Therapeutics under review for listing on TSX | 2 | Stockwatch | ||
16.04. | Antibe Therapeutics Inc. Announces TSX Delisting Review | 88 | Business Wire | TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX: ATE) announced that the Toronto Stock Exchange ("TSX") is reviewing the eligibility for continued listing on... ► Artikel lesen | |
10.04. | Antibe Therapeutics Inc (2): Antibe Therapeutics granted initial order under CCAA | 1 | Stockwatch | ||
09.04. | Antibe Therapeutics Inc (2): Antibe Therapeutics under TSX delisting review | 1 | Stockwatch | ||
09.04. | Antibe Therapeutics Inc (2): Antibe Therapeutics to resume at 9:15 a.m. PT | 1 | Stockwatch | ||
09.04. | Antibe Therapeutics Inc (2): Antibe to file for initial order under CCAA | 1 | Stockwatch | ||
09.04. | Antibe Therapeutics Inc (2): Antibe Therapeutics halted at the open | 1 | Stockwatch | ||
09.04. | Antibe Therapeutics Inc. Announces Granting of Initial Order Under Companies' Creditors Arrangement Act | 53 | Business Wire | TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX: ATE, OTCQX: ATBPF) announced that its previously announced application for an Initial Order under the Companies'... ► Artikel lesen | |
01.04. | Antibe Therapeutics Inc (2): Antibe's otenaproxesul placed on clinical hold by FDA | 4 | Stockwatch | ||
01.04. | Antibe Therapeutics Inc. Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance | 41 | Business Wire | TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe" or the "Company" TSX: ATE, OTCQX: ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the... ► Artikel lesen | |
04.03. | Antibe Therapeutics placed "Under Review" at Echelon | 2 | Cantech Letter | ||
04.03. | Antibe Therapeutics Inc (2): Antibe ordered to refund Nuance's $20M (U.S.) payment | 5 | Stockwatch | ||
28.02. | Antibe Therapeutics has more upside still, Paradigm says | 3 | Cantech Letter | ||
14.02. | Antibe Therapeutics Inc (2): Antibe spends $2.3-million on R&D in Q3 2024 | 1 | Stockwatch | ||
14.02. | Antibe Therapeutics Non-GAAP EPS of -C$0.08 | 1 | Seeking Alpha | ||
14.02. | Antibe Therapeutics Inc. Reports Q3 2024 Interim Financial and Operating Results | 180 | Business Wire | TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, has... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
EVOTEC | 3.967 |
NVIDIA | 2.790 |
TUI | 2.201 |
GAMESTOP | 1.964 |
BAYER | 1.646 |
NEL | 1.569 |
RHEINMETALL | 1.381 |
BYD | 1.186 |
DEUTSCHE LUFTHANSA | 1.071 |
TESLA | 802 |
VOLKSWAGEN | 771 |
CARL ZEISS MEDITEC | 638 |
BASF | 607 |
APPLE | 589 |
SNOWFLAKE | 587 |
COMMERZBANK | 578 |
THYSSENKRUPP | 573 |
AIXTRON SE | 568 |
DEFI TECHNOLOGIES | 564 |
PORSCHE SE | 564 |
SUPER MICRO COMPUTER | 561 |
CAVENDISH HYDROGEN | 497 |
DEUTSCHE BANK | 485 |
MERCEDES-BENZ | 480 |
ALLIANZ | 467 |